UPC_CFI_123/2024

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Provisional measuresProvisional MeasuresHamburg LDProvisional measuresCase Closed

Overview Decisions Reasoning Citations Documents Timeline

Parties

Claimants

Alexion Pharmaceuticals, Inc.(AstraZeneca Group)

Reps: Elena Hennecke

Respondents

Samsung Bioepis NL B.V.

Reps: Andrea Ritter

Judges

Sabine Klepsch
Alima Zana
Stefan Schilling
Rudi Goedeweeck

Patents

EP3167888

CPC codes: A61P31/04, A61P25/18, A61P29/02, A61K39/395, A61K2039/505, A61P7/02, A61P25/26, A61P13/02, A61P15/10, A61P17/00, A61P7/00, A61P25/28…

Sector: Organic Chemistry

Outcome

PI denied

Filed: Mar 19, 2024

First decided: Jun 26, 2024

Language: English

The Hamburg Local Division dismissed Alexion Pharmaceuticals' application for a preliminary injunction against Samsung Bioepis based on EP 3 167 888, finding that while direct infringement could be established, the court could not be sufficiently certain of the patent's validity given the EPO Technical Board of Appeal's history of rejecting correction requests for SEQ ID NO:4, and thus denied the measure.

Open on UPC Registry